CTI BioPharma (NASDAQ:CTIC) is set to announce its earnings results after the market closes on Wednesday, February 28th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter.
Shares of CTI BioPharma (CTIC) opened at $3.80 on Monday. CTI BioPharma has a 12 month low of $2.45 and a 12 month high of $4.65. The company has a market cap of $239.31, a P/E ratio of -3.19 and a beta of 0.50. The company has a quick ratio of 2.17, a current ratio of 2.19 and a debt-to-equity ratio of 0.26.
In other CTI BioPharma news, insider Value Fund L. P. Biotechnology bought 6,333,333 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was bought at an average cost of $3.00 per share, for a total transaction of $18,999,999.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Bvf Partners L. P/Il bought 5,634,108 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were acquired at an average price of $3.00 per share, with a total value of $16,902,324.00. The disclosure for this purchase can be found here. Insiders own 2.16% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “CTI BioPharma (CTIC) to Release Quarterly Earnings on Wednesday” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3222338/cti-biopharma-ctic-to-release-quarterly-earnings-on-wednesday.html.
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.